After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...

Biogen does not undertake any obligation to publicly update any forward-looking statements. LEQEMBI (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc ...

Biogen and Eisai have announced that the US Food and Drug ... maintenance dosing in patients who have completed the bi-weekly IV initiation phase, with the injection process expected to take 15 ...

The FDA has started its review of a subcutaneous injection formulation of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to receive maintenance doses at home, rather than in ...

The cash injection comes as Biogen has been hit hard by the stalled rollout of its Alzheimer's disease drug Aduhelm (aducanumab), with Stat reporting earlier this month that the company is ...

The injection process is expected to take ... s development and regulatory submissions globally. Eisai and Biogen co-commercialize and co-promote the product, and Eisai has the final decision ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Biogen shares soared 44 percent on a single ... The company is also evaluating a follow-on drug, known as remternetug, via injection as well as infusion. The late-stage trial will assess the ...